Can anti-rejection drugs prevent sensitization after a failed kidney transplant?
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study is for people whose first kidney transplant has stopped working and who need to start dialysis. The goal is to see if continuing certain anti-rejection medications can help prevent the body from making antibodies that would make it harder to get another transplant in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older and your first kidney transplant has failed.
- You are about to start dialysis as a result.
- You were taking either tacrolimus or cyclosporine to prevent rejection after your transplant.
- You have not had any other organ transplant or more than one kidney transplant.
- You do not have an active infection or cancer that would prevent you from staying on anti-rejection drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a blood test called Prospera can help doctors safely lower the amount of anti-rejection medicines you take after a kidney transplant. It is for people who recently received a kidney and are on standard anti-rejection drugs.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This trial is testing a stronger combination of four immune-suppressing medicines (including mTOR inhibitors) to help prevent rejection in kidney transplant patients who have a high level of antibodies. It aims to see if this approach works better than standard care for these 'sensitized' patients.
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
This study compares what happens when patients with a failed kidney transplant (still in the body) stop their immunosuppressant medicines at 6 months versus continuing them. The goal is to safely prevent your immune system from becoming too sensitive, which can make finding a new donor kidney harder.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.